Kornimate/medical-research-clean huggingface dataset:
antenatal body shape index and pregnancy complications

Conditions: Gestational Complications; Body Mass Index; Waist Circumference; Gestational Hypertension; Gestational Diabetes Mellitus (GDM); Preeclampsia (PE)

Summary: background/aim: gestational diabetes (gdm), gestational hypertension (ght) and preeclampsia are common complications of pregnancy. in this study, it was aimed to determine the relationship between body shape index (absi), calculated based on antenatal measurements of the height, weight and waist circumference, and gdm, ght and preeclampsia. materials and methods: 170 patients at 6-16th weeks of gestation were prospectively analyzed. body mass index (bmi) and absi were calculated. patients were analyzed according to the presence of gdm, ght and preeclampsia at follow-up. our study is the first in terms of its subject and makes a significant contribution to the literature.


Eligibility criteria:
inclusion criteria: * having a singleton pregnancy * pregnancy follow-up and birth must have taken place at bolu abant i̇zzet baysal university training and research hospital. * voluntary informed consent form must be signed to participate in the study. exclusion criteria: * multiple pregnancies * additional systemic and chronic diseases (chronic hypertension, dm, hepatic diseases such as cholestasis, cardiac diseases, rheumatic diseases, renal diseases...) * history of gestational diabetes, gestational hypertension and preeclampsia in previous pregnancies

Keywords: gestational hypertension gestational diabetes preeclampsia body shape index waist circumference
observational study of allergic rhinitis in children

Conditions: Allergic Rhinitis

Summary: observational, cross-sectional, prospective, multicentric study in france with private paediatricians to describe the management of allergic rhinitis in children.

data collected about diagnostic, comorbidities, clinical history, management of allergic rhinitis using a patient paper case report form. there is only one visit per patient and investigators can include up to 10 patients.

Eligibility criteria:
inclusion criteria: * under 18 years of age * with allergic rhinitis * who's representative of the parental authority did not object to his child's participation after oral and written information and who agrees to participate exclusion criteria: * child or adolescent opposed to participate or collect his personal data
clinical outcome of pacemaker patients according to pacing modality and primary indications opti-mind 2

Conditions: Bradyarrhythmia

Summary: the purpose of the study is to demonstrate that reduction of unnecessary pacing provided by rythmiq algorithm programed to on in a pacemaker is associated with better clinical outcomes in bradycardia target population.


Eligibility criteria:
inclusion criteria: 1. patients implanted with any of bsc dual chamber pm devices equipped with rhytmiq with the algorithm programed to on based on clinical indication at the time of discharge from the hospital 2. patients who are willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational center 3. patients whose age is 18 years or above, or of legal age to give informed consent specific to state and national law exclusion criteria: 1. patients with 3rd degree av block 2. patients with permanent af 3. patients followed up remotely with remote patient management system. 4. patients who are unable to be followed up by the participating centers for a period of two years 5. patients who have a current device implanted for more than 15 days 6. women of childbearing potential who are pregnant, or plan to become pregnant during the time of the study (method of assessment upon physician's discretion) 7. patients who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the patient is participating in a mandatory governmental registry or extensions/amendments of the current protocol.
fermented plant-based portfolio diet 4 metabolic health

Conditions: Metabolic Cardiovascular Syndrome

Summary: the primary objective of this study is to evaluate the metabolic effects of a high-fiber portfolio diet based on fermented plant-based foods compared to a corresponding non-fermented plant-based diet and a control diet (habitual diet). this will be assessed across gut microbiome profiles (high/low prevotella), focusing on cardiometabolic risk factors, particularly inflammation. a total of 100 men and women who meet all inclusion criteria and none of the exclusion criteria will be invited to participate. the study will employ a three-way randomized, controlled cross-over design, featuring six-week interventions separated by six-week washout periods. participants will attend the clinic on 15 occasions, including screening visits.


Eligibility criteria:
inclusion criteria: * sign of metabolic syndrome waist circumference \> 102 cm/88 cm m/w and at least one of the following: * high density lipoprotein (hdl) ≤1.0 mmol/l men / hdl ≤1.3 mmol/l * triglycerides ≥ 1,7 mmol/l * blood pressure ≥130/85 mmhg * fasting glucose ≥5.6 mmol/l other inclusion criteria: * signed informed consent * willingness to consume the intervention foods * body mass index 25-35 kg/m2 * hemoglobin 120-160 g/l * serum thyroid-stimulating hormone (s-tsh) \<4 miu/l * serum c-reactive protein (s-crp) \<5 mg/l * access to a -18⁰ c freezer * any medication stable for the last 14 days. exclusion criteria: * blood donation or participation in a clinical study with blood sampling within 30 days prior to screening visit and throughout the study. * following any weight reduction program or having followed one during the last 6 months * food allergies or intolerances * history of stomach or gastrointestinal conditions (inflammatory bowel disease, crohn's disease, malabsorption, colostomy, bowel resection, gastric bypass surgery, helicobacter infection, peptic ulcer disease, untreated celiac disease, etc.) * previous major gastrointestinal surgery * pregnant or lactating or wish to become pregnant during the period of the study. * unable to understand written and spoken swedish * lack of suitability for participation in the trial, for any reason, as judged by the medical doctor or pi. * pharmacological medication with drugs known to affect the microbiota, e.g., antibiotics, within 6 months prior to baseline. * intake of any probiotic pills or foods enriched in probiotics within 6 months prior to baseline. * type i diabetes * small bowel bacterial overgrowth * diarrheal disease * receiving pharmacological treatment for type ii diabetes (treatments based on lifestyle interventions are acceptable, as long as it is compatible with the study protocol) * using nicotine products on a daily basis (including chewing gum, patches, snus etc.) * history of heart failure or heart attack (tia) within 1 year prior to screening * thyroid disorder * planned surgery within the next eight months
identifying molecular alterations to guide individualized treatment in advanced solid tumors

Conditions: Neoplasm Metastasis

Summary: permed01 is a prospective monocenter clinical trial which aims to evaluate the number patients with locally advanced or metastatic cancer for whom identification of molecular alterations in tumor samples can lead to the delivery of a targeted therapy. permed01 will enroll 460 patients in 3 years.


Eligibility criteria:
inclusion criteria: * age\>18 years * histological diagnosis of cancer * locally advanced or metastatic, biopsiable disease * ecog performans status ≤2 * affiliation to social security * signed informed consent. exclusion criteria: * emergency, individually deprived of liberty or placed under the authority of a tutor * patients with symptomatic or progressive brain metastasis * patients who have only bone and/or brain metastases * pregnant or breastfeeding women
dexmedetomidine versus fentanyl as adjuvants to bupivacaine in ultrasound guided transversus abdominis plane block

Conditions: Pain

Summary: the aim and objective of this study is to compare dexmedetomidine and fentanyl as adjuvants to bupivacaine in ultrasound guided tap block analgesia in patients undergoing radical cystectomy as regarding postoperative analgesic efficacy.

radical cystectomy with pelvic lymph node dissection is the gold standard treatment for muscle invasive bladder cancer and is associated with a high risk of complications. management of the postoperative pain is important to decrease the length of stay in the hospital and the risk of morbidity. multimodal analgesia management is utilized for pain observed in the postoperative period.as part of a multimodal analgesic regimen, a peripheral nerve block can decrease opioid consumption, providing more effective analgesia with fewer adverse effects.tap block is a relatively new regional anesthesia technique that provides analgesia to the parietal peritoneum, as well as skin and muscles of the lower anterior abdominal wall. dexmedetomidine and fentanyl have been used as adjuvants to local anesthetics in different surgeries to provide superior analgesia and to improve the duration of the block.

Eligibility criteria:
inclusion criteria: * both sexes. * asa grade i and ii. * age between 50-70 years. * elective open radical cystectomy. exclusion criteria: * any history or signs of cardiac, hepatic and renal failure. * patients with coagulopathy or under anticoagulation therapy. * infection near the site of needle insertion. * morbid obesity (bmi\>40 kg/m2). * history of allergic reactions to any of the study medications. * previous abdominal surgery. * patients with any neurological or neuromuscular disorder or history of seizures.

Keywords: dexmedetomidine fentanyl bupivacaine transversus abdominis plane block
matrix metalloproteinases in atherosclerosis of chronic kidney disease

Conditions: Diabetic Nephropathy

Summary: the purpose of this study is to determine whether matrix metalloproteinases are associated with atherosclerosis in the different stages of chronic kidney disease.

the purpose of this study is to determine the correlation of matrix metalloproteinases and atherosclerosis of chronic kidney disease. patients with diabetes mellitus type 2,as a non-inflammatory leading cause of end stage renal failure and patients with chronic glomerulonephritis and similar course of proteinuria,as an inflammatory leading cause of end stage renal failure are enrolled.

Eligibility criteria:
inclusion criteria: * chronic kidney disease * diabetes mellitus type 2 exclusion criteria: * malignancy

Keywords: gelatinases kidney disease diabetes mellitus type 2
a phase i/ii to assess safety, tolerability and efficacy of dl-lactic acid syrup in children with recurrent tonsillitis

Conditions: Recurrent Tonsillitis in Children

Summary: the study objectives are to evaluate tonsitin™ (10% lactic acid) safety, tolerability and preliminary efficacy, as a potent treatment for recurrent tonsillitis in children.


Eligibility criteria:
inclusion criteria: * children at the ages of 5-16. * patient is suffering from recurrent documented sore throat with at least 4 tonsillitis episodes during the preceding year (at least one verified by culture or rapid antigen testing for streptococcus a). * patient with clinical presentation of irregular tonsils. * tonsils size graded between 2.5-4. * clinical diagnosis of bacterial known in recurrent pharyngeal-tonsillitis. * patient is willing to participate in the study and adhere to the study protocol * patient's guardian and/or patient have signed informed consent. exclusion criteria: * clinical diagnosis of acute tonsillitis/pharyngitis caused by streptococcus pyogenes (positive rsat or microbial culture). * subjects who are known as streptococcus pyogenes carriers * subject's requiring any other medication (topical or systemic) that may affect the course of the disease during the study period (e.g. antibiotics, sedating antihistamines), and/or did not completed 14 days from end of antibiotics treatment. * subjects with known hypersensitivity to lactose. * subject is suffering from peritonsillar abscess. * subject suffers from an active peptic ulcer * subjects who are suffering from any concomitant disease which in the judgment of the investigator will interfere with the conduct or interpretation of the study results. * subject is currently participating in another clinical study.

Keywords: recurrent tonsillitis streptococcus a
routine coronary catheterization in low extremity artery disease undergoing percutaneous transluminal angioplasty

Conditions: Peripheral Artery Disease; Coronary Artery Disease

Summary: 1. the prevalence of significant and complex obstructive coronary artery disease (cad) is high in patients who have low extremity artery disease (lead). 2. long-term prognosis of lead undergoing percutaneous transluminal angioplasty (pta) remains poor and cad is an independent predictor of total mortality after pta. 3. this prospective randomized controlled trial will evaluate the prognostic effects of routine versus selective coronary angiography before pta for lead and elucidate the potential mechanism.

1. participants 1. eligible participants are randomly assigned to systemic strategy or selective strategy * participants allocated to systemic strategy will receive routine coronary angiography before pta without a previous non-invasive stress test * subjects allocated to selective strategy will undergo non-invasive evaluation of possible myocardial ischemia by using dobutamine stress echocardiography (dse) or dipyridamole thallium 201 myocardial perfusion scintigraphy (dts) followed by coronary angiography if the test is positive for ischemia 2. participants who are not willing to be randomized will be included in the registration group 2. revascularization 1. a staged approach (myocardial revascularization first followed by pta) and simultaneous approach (percutaneous coronary intervention immediately followed by pta at the same time if clinically suitable) are both allowed 2. the duration from revascularization to pta should be within 60 days 3. percutaneous coronary intervention is performed at the time of coronary angiography, using bare metal or drug-eluting stents 3. blood sampling, genotyping, and measurement of biomarkers and microrna a. bood samples (20 ml) are obtained from peripheral arteries in all study subjects before pta and 10 ml after pta and are prepared and stored for enzyme-linked immunosorbent assay (elisa), genotyping and measurement of micrornas in plasma and peripheral blood mononuclear cells 4. outcome follow-up a. clinical outcomes are obtained by chart review if the patient is still in the hospital and followed up by clinic visit, telephone call or direct contact with participants or subjects' family at 30 days after indexed pta if the patient has been discharged from the hospital and every 6 months thereafter

Eligibility criteria:
inclusion criteria: * known lead (documented by previous angiography or sonography performed by the operators) admitted for elective pta exclusion criteria: * known cad or unstable angina within past 3 months * acute myocardial infarction within past 6 months * known cad status posterior percutaneous coronary intervention or bypass surgery within past 6 months * planning to do bypass surgery for known lead\\ * pregnancy * documented active malignancy * needing emergency pta

Keywords: coronary artery disease peripheral artery disease percutaneous transluminal angioplasty coronary angiography revascularization gene polymorphisms micrornas
assessing the effects of hba1c reduction on alleviating nonspecific back pain

Conditions: Back Pain Lower Back Chronic; Back Pain; Pre Diabetes; Diabetes; Back Pain, Low

Summary: prediabetes, characterized by elevated hba1c levels, is a common precursor to type 2 diabetes mellitus. recent studies have suggested a potential link between prediabetes and nonspecific back pain. this randomized controlled trial aimed to assess whether reducing hba1c levels through lifestyle interventions and, along with the correction of vitamin d and magnesium, can alleviate nonspecific back pain in prediabetic patients.

the study included 40 patients from an outpatient clinic in baghdad, evenly divided into intervention and control groups. the intervention group underwent a 6-month lifestyle modification program, focusing on diet, sleep, exercise, and vitamin d and magnesium correction. hba1c levels were measured, and back pain severity was assessed (through what assessment method ?). the control group received standard care with nsaids and acetaminophen for pain management. assessments were conducted at baseline and at various intervals over a total period of 6 months to evaluate changes in hba1c levels and back pain intensity. this randomized controlled trial provides evidence that reducing hba1c levels through lifestyle modifications, along with the correction of vitamin d and magnesium, can lead to a reduction in nonspecific back pain intensity and improved functional outcomes in prediabetic patients.

Eligibility criteria:
inclusion criteria: * poor sleep (less than 6 hours per day) * chronic back pain * multiple joint pain * non-specific back pain * hba1c more than 5.7 * ability to record the data exclusion criteria: * not able to record data * previous spine surgeries * severe oa in knee * spinal stenosis * peripheral vascular diseases * rheumatological diseases * lumbar disc prolapse * uncooperative patient

Keywords: back pain hba1c
the effects of hypoxic burden on executive function (ef) in preschool children with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea (OSA)

Summary: the goal of this observational study is to study the effect of hypoxic burden on executive function in preschool children aged 2-6 years who have osa. the main question it aims to answer is effect of hypoxic burden from osa to executive function measured by brief-p in preschool children..

there is no comparison group in this study participants will performed full night polysomnography, denver and brief-p test within 3 months.

Eligibility criteria:
inclusion criteria: * children aged 2-6 years old with osa exclusion criteria: * underlying diseases : hypoventilation, neuromuscular diseases, etc.
side-specific factors for conversion in adrenalectomy for pheochromocytoma.

Conditions: Adrenal Tumor

Summary: context: adrenalectomy for pheochromocytoma (pheo) poses difficulties due to the elevated chance of conversion. the objective of this study was to conduct a comparative analysis of the occurrence and determinants of conversion in left-sided abdominal laparoscopic adrenalectomy (lla) and right-sided abdominal laparoscopic adrenalectomy (rla). methods: a retrospective analysis was conducted to include a total of 271 patients diagnosed with pheo. these patients were separated into two groups: lra (n=121) and lla (n=150). the study period spanned from september 2016 to september 2023.

the process of performing an adrenalectomy for pheochromocytoma (pheo) is difficult due to the significant risk of conversion. the objective of this study was to conduct a comparative analysis of the occurrence and determinants of conversion in left-sided abdominal laparoscopic adrenalectomy (lla) and right-sided abdominal laparoscopic adrenalectomy (rla). methods: a retrospective analysis was conducted to include a total of 271 patients diagnosed with pheo. these patients were separated into two groups: lra (n=121) and lla (n=150). the study period spanned from september 2016 to september 2023.

Eligibility criteria:
inclusion criteria: * unilateral pheochromocytoma of any size, over 18 years old, both males and females exclusion criteria: * patients undergoing initial open adrenalectomy, - additional surgical interventions during total laparoscopic adrenalectomy, - partial adrenalectomy, bilateral pheos. hemorrhagic diathesis, structural deformity pregnancy, - prior unilateral abdominal surgery, data is absent. the preoperative diagnosis is ambiguous. hereditary (pheo), or recurrent pheo
a study to evaluate the efficacy and safety of autogene cevumeran (ro7198457) in combination with pembrolizumab versus pembrolizumab alone in participants with previously untreated advanced melanoma.

Conditions: Advanced Melanoma

Summary: this study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (pros) of autogene cevumeran (ro7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.


Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic (recurrent or de novo stage iv) or unresectable locally advanced (stage iiic or iiid) cutaneous, acral, or mucosal melanoma; * eastern cooperative oncology group (ecog) performance status of 0 or 1; * life expectancy \>/= 12 weeks; * adequate hematologic and end-organ function; * naive to prior systemic anti-cancer therapy for advanced melanoma with some exceptions; * tumor specimen availability; * measurable disease per recist v1.1. exclusion criteria: * ocular/uveal melanoma; * any anti-cancer therapy with the exceptions as specified in the protocol; * symptomatic, untreated, or actively progressing central nervous system (cns) metastases; * previous splenectomy; * history of autoimmune disease; * prior allogeneic bone marrow transplantation or prior solid organ transplantation; * positive test for human immunodeficiency virus (hiv) infection; * active hepatitis b or c or tuberculosis; * significant cardiovascular disease; * known clinically significant liver disease.
potential therapeutic implications of laser acupoints on visceral fat and hormonal changes in post-menopausal women

Conditions: Post-menopausal Women; Visceral Fat

Summary: potential therapeutic implications of laser acupoints on visceral fat and hormonal changes in post-menopausal women

all the patients fitted the inclusion criteria, will be given explanation of the treatment protocol in their understandable language. treatment procedures. group (a): will receive laser acupuncture in addition to traditional treatment (low calorie-diet and physical activity) group (b): will receive traditional treatment only laser acupuncture technique: application of laser acupuncture on 10 acupuncture procedure for each woman which will be detected by therapist according to acupuncture points will stimulate st 25 (tianshu), st 36 (zusanli), liv 3 (taichong); p 6 (neiguan), h 7 (shenmen) for the psychical aspect of the therapy and auriculothera- py: 55 (shenmen) and 87 (stomach) each point stimulating will be stimulation time, 30 s/point two sessions per week for 8 weeks.

Eligibility criteria:
inclusion criteria: * post-menopausal women * woman with visceral obesity * with age ranges from 50-65years * body mass index (bmi) more than 30 kg/m2 * whr more than 0.8 exclusion criteria: * endometrial cancer * insulin resistance * or metabolic disorders * diabetes * hypertensive •not receiving any medication of obesity